[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Apsen Farmaceutica S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632659","phase-3-efficacy-and-safety-of-apsmnf-in-the-treatment-of-male-androgenetic-alopecia-100632659",false,"NCT07516561","Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia","Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia","MONA","Inclusion Criteria:\n\n* Men aged 18 to 60 years with a clinical diagnosis of androgenetic alopecia ;\n* Participants who use an acceptable contraceptive method, or who declare that their partner uses an acceptable contraceptive method, according to the protocol, and who agree to use it throughout the study period.\n\nExclusion Criteria:\n\n* History of allergic reactions to any of the active ingredients or to any of the ingredients of teh formulation;\n* Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;\n* Participants with conditions that may affect hair growth or with underlying conditions that cause hair loss, such as a diagnosis of alopecia areata, fibrosing or cicatricial alopecia, or telogen effluvium, the latter being present at the time of screening;\n* Participants with concomitant inflammation or other dermatological conditions of the scalp, such as moderate or severe psoriasis or seborrheic dermatitis, and\u002For active infection and\u002For keloid formation in the area of alopecia;","MALE","18 Years","60 Years",{"count":21,"type":22},336,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.",[28],"Alopecia, Androgenetic","NOT_YET_RECRUITING","2026-04-07",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":22},"2026-07-07",{"date":37,"type":22},"2029-08-02",{"name":39,"class":40},"Apsen Farmaceutica S.A.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100625298","phase-2-efficacy-and-safety-of-apstzd-in-the-treatment-of-insomnia-disorder-100625298","NCT07420816","Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","TINA","Inclusion Criteria:\n\n* Participants aged between 18 and 64 years;\n* Participants diagnosed with insomnia disorder according to the criteria defined by the DSM-V (1) and who report sleep maintenance disorder;\n* Participants who agree not to use alcoholic beverages during the entire treatment period (6 weeks).\n\nExclusion Criteria:\n\n* Participants with known hypersensitivity to the active ingredients used during the trial or who have exhibited complex sleep behavior after using them;\n* Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;\n* Women who are pregnant or breastfeeding, as well as women who have a positive result on a pregnancy test (β-hCG) during the screening period of the trial;\n* Participants diagnosed with severe liver failure;","ALL","64 Years",{"count":53,"type":22},222,[55],"PHASE2","The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.",[58,59],"Insomnia","Insomnia Chronic","2026-02-12",{"date":62,"type":33},"2026-02-19",{"date":64,"type":22},"2026-03-26",{"date":66,"type":22},"2027-09-23",{"name":39,"class":40},""]